GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm Boston Pharmaceuticals, the British drugmaker said on Wednesday. Efimosfermin, a monthly subcutaneous injection,

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the promising field of liver therapies.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals’ efimosfermin, a drug ready to hit Phase III trials for the treatment of liver disease.